PHASE I/II STUDY OF OSI-774 AND CCI-779 IN RECURRENT MALIGNANT GLIOMA

OSI-774 和 CCI-779 在复发性恶性胶质瘤中的 I/II 期研究

• 批准号: 7607538
• 负责人: MINESH P. MEHTA
• 金额: $ 0.49万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607538
• 关键词: Adverse effects; CCI-779; Computer Retrieval of Information on Scientific Projects Database; Dose; Enzymes; Erlotinib; Funding; Grant; Growth; Institution; Malignant Glioma; Patients; Phase; Phase I/II Trial; Recurrence; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Work; cell growth; neoplastic cell

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This Phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurrent malignant glioma.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 （摘自ClinicalTrials.gov网站） Erlotinib和Temsirolimus，可能通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。 该阶段I/II试验正在研究与Erlotinib一起进行的副作用和最佳剂量，并了解它们在治疗复发性恶性神经胶质瘤患者方面的工作状况。